Most Popular
Sponsored
TYRA's 280% surge continues as HighVista adds shares. Preclinical biotech, no revenue, but strong cash runway.
ZBH revenue up 9.3% but stock drops 10.7%; STE revenue up 7.3%, stock up 4.6%. Mixed results.
Thames Water's £10B rescue deal faces political paralysis risk. Investors fear delays could push it to nationalization.
GPCR up 60% on obesity drug data, but HighVista sells $4.7M amid high valuation.
PGNY beats Q1 estimates on revenue & profit; margin expands despite lower sales volumes. Buy?
Hormuz oil flows creep higher as Brent crude jumps 50%. Iran-US talks stall, raising supply risks.
ALMS up 400% on strong data, but high expectations mean risk. Fund adds $8M.
Sponsored
Must Read